نتائج البحث - David W. Hutton

تنقيح النتائج
  1. 1
    Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China

    Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China حسب David W. Hutton, Samuel So, Margaret L. Brandeau

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States

    Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States حسب Paul M. Stranges, David W. Hutton, Curtis D. Collins

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Cost effectiveness of regorafenib as second‐line therapy for patients with advanced hepatocellular carcinoma

    Cost effectiveness of regorafenib as second‐line therapy for patients with advanced hepatocellular carcinoma حسب Neehar D. Parikh, Amit G. Singal, David W. Hutton

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Cost-Effectiveness of Universal Routine Depression Screening for Adolescents in Primary Care

    Cost-Effectiveness of Universal Routine Depression Screening for Adolescents in Primary Care حسب Tran T. Doan, David W. Hutton, Davene R. Wright, Lisa A. Prosser

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms

    Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms حسب Neehar D. Parikh, Amit G. Singal, David W. Hutton, Elliot B. Tapper

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma

    Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma حسب Joshua D. Stein, David D. Kim, Will W. Peck, Steven M. Giannetti, David W. Hutton

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis

    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis حسب Anton L.V. Avanceña, Nicholas Miller, Sarah Uttal, David W. Hutton, Jessica L. Mellinger

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

    Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration حسب Joshua D. Stein, Paula Anne Newman-Casey, Mrinalini Tavag, Paul P. Lee, David W. Hutton

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence

    Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence حسب David D. Kim, David W. Hutton, Ahmed A. Raouf, Mohsen Salama, Ahmed Hablas, Ibrahim A. Seifeldin, Amr S. Soliman

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema

    Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema حسب Joshua D. Stein, Paula Anne Newman-Casey, David D. Kim, Kristen Nwanyanwu, Mark W. Johnson, David W. Hutton

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment

    Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment حسب Eric L. Ross, David W. Hutton, Joshua D. Stein, Neil M. Bressler, Lee M. Jampol, Adam R. Glassman

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

    Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy حسب David W. Hutton, Joshua D. Stein, Neil M. Bressler, Lee M. Jampol, David J. Browning, Adam R. Glassman

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma

    Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma حسب Wei‐Ting Liao, Jiaxing Huang, David W. Hutton, Guiqi Zhu, Qiuji Wu, Feng Wen, Liangliang Bai, Qiu Li

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy

    Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy حسب David W. Hutton, Joshua D. Stein, Adam R. Glassman, Neil M. Bressler, Lee M. Jampol, Jennifer K. Sun

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30

    Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30 حسب David Tordrup, Yvan Hutin, Karin Stenberg, Jeremy A. Lauer, David W. Hutton, Mehlika Toy, Nick Scott, Marc Bulterys, Andrew Ball, Gottfried Hirnschall

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States

    Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States حسب Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica A. Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Impact of the national hepatitis B immunization program in China: a modeling study

    Impact of the national hepatitis B immunization program in China: a modeling study حسب Zhixi Liu, Mengying Li, David W. Hutton, Abram L. Wagner, Ye Yao, Wenlong Zhu, Lingsheng Cao, Shenglan Tang, Jinhua Pan, Yesheng Wang, Qi Zhao, Hong Ren, Ying Wang, Weibing Wang

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry

    Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry حسب Roland E Schmieder, Felix Mahfoud, Giuseppe Mancia, Krzysztof Narkiewicz, Luís M. Ruilope, David W. Hutton, Khoa N. Cao, Douglas A. Hettrick, Martin Fahy, Markus P. Schlaich, Michael Böhm, Jan B. Pietzsch

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

    Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 حسب Amadea Britton, Lauren E. Roper, Camille N. Kotton, David W. Hutton, Katherine E. Fleming-Dutra, Monica Godfrey, Ismael R. Ortega-Sánchez, Karen R. Broder, H. Keipp Talbot, Sarah S. Long, Fiona P. Havers, Michael Melgar

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    The burden of Chronic Pelvic Pain (CPP): Costs and quality of life of women and men with CPP treated in outpatient referral centers

    The burden of Chronic Pelvic Pain (CPP): Costs and quality of life of women and men with CPP treated in outpatient referral centers حسب David W. Hutton, Aida Mustafa, Soha Patil, Saira Rathod, Gautam Shrikhande, Arnold P. Advincula, Jessica Drummond, Peter K. Gregersen, Jason Hall, Christine N. Metz, Alexandra Milspaw, Iris Kerin Orbuch, Peter J. Stahl, Joshua Epstein, Allyson Shrikhande

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: